Effects of antithrombin III and antivenom on procoagulant activity of Russell's viper venom in a whole blood model.
The procoagulant activities of Russell's viper venom were assessed in an in vitro whole blood model. Sequential samplings showed that the generation of fibrinopeptide A (FPA), a marker of thrombin activity, and platelet factor 4 (PF4), a marker of platelet activity, exhibited bi-phasic kinetics with an initial slow phase followed by a rapid phase of secretion. In the presence of Russell's viper venom, the generation of both FPA and PF4 was accelerated with the bi-phasic kinetics of PF4 being maintained while that of FPA completely disappeared. Administration of either antivenom (1,600 ng) or 10 IU antithrombin III (AT-III) had no antagonistic effect against the venom but combination of both resulted in a significant prolongation of both FPA and PF4 release (p < 0.05). High dose AT-III (20 IU) resulted in normalization of both FPA and PF4 kinetics and serial levels of both parameters were lower than those treated with the combined regimen, although these were not statistically significant. Unlike the untreated venom activated whole blood, there was no clot formation following treatment with either the combined regimen or high dose AT-III. The results of this study suggested that the effect of Russell's viper venom on the clotting cascade is more potent and direct than that on platelet activity. There were complementary effects between antivenom and AT-III is controlling of both FPA and PF4 release induced by the venom. Furthermore, in this in vitro experiment, AT-III alone when administered in a sufficient dose, abolished the procoagulant effects of Russell's viper venom.
Clemens
R
R
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Lorenz
R
R
Pukrittayakamee
S
S
Punpoowang
B
B
Vanijanonta
S
S
Charoenlarp
P
P
D000818:Animals; D000990:Antithrombin III / Q000494:pharmacology*; D000997:Antivenins / Q000494:pharmacology*; D015415:Biomarkers; D001777:Blood Coagulation; D005344:Fibrinopeptide A / Q000378:metabolism; D006487:Hemostasis / Q000502:physiology; D066298:In Vitro Techniques; D008954:Models, Biological; D010978:Platelet Factor 4 / Q000378:metabolism; D017840:Daboia; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D012909:Snake Bites / Q000097:blood / Q000150:complications; D018709:Statistics, Nonparametric; D013917:Thrombin / Q000378:metabolism; D014757:Viper Venoms / Q000037:antagonists & inhibitors* / Q000097:blood / Q000201:enzymology
D000997:Antivenins; D015415:Biomarkers; D015842:Serine Proteinase Inhibitors; D014757:Viper Venoms; D005344:Fibrinopeptide A; D010978:Platelet Factor 4; D000990:Antithrombin III; D013917:Thrombin